4.6 Article

Management of Clinically Involved Lateral Lymph Node Metastasis in Locally Advanced Rectal Cancer: A Radiation Dose Escalation Study

期刊

FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.674253

关键词

locally advanced rectal cancer; lateral lymph node; lateral lymph node dissection; dose escalation; MRI

类别

资金

  1. National Natural Science Foundation for Young Scholars of China [81703080]
  2. Sixth Affiliated Hospital of Sun Yat-Sen University Clinical Research 1010 Program [1010PY (2020)-09]

向作者/读者索取更多资源

The study compared the efficacy of three neoadjuvant therapeutic regimens for LLNs metastasis of locally advanced rectal cancer and found that radiation dose boost is effective in increasing response rate and decreasing recurrence rates. A short axis of LLNs in restaging MRI is an independent risk factor for prognosis.
Background Patients with lateral lymph nodes (LLNs) metastasis are not effectively treated with neoadjuvant chemoradiotherapy. This study aimed to compare the efficacy of three neoadjuvant therapeutic regimens, namely, chemotherapy, chemoradiotherapy, and chemoradiotherapy with a dose boost of LLNs, and to identify the optimal approach for treating LLNs metastasis of locally advanced rectal cancer. Methods A total of 202 patients with baseline LLNs metastasis (short axis < 5 mm) and treated with neoadjuvant treatment, followed by radical surgery from 2011 to 2019, were enrolled. The short axis of the LLNs on baseline and restaging MRI were recorded. Survival outcomes were compared. Results In the booster subgroup, shrinkage of LLNs was significantly greater than in the neoadjuvant chemotherapy and chemoradiotherapy subgroups (P < 0.001), without increasing radiation related side effects (P = 0.121). For patients with baseline LLNs of short axis >= 5 mm in the booster subgroup, the response rate (short axis < 5 mm on restaging MRI) was 72.9%, significantly higher than patients in the neoadjuvant chemotherapy subgroup (48.9%, P = 0.007) and higher than for patients in the neoadjuvant chemoradiotherapy group (65.0%), but there was no statistical difference (P = 0.411). The 3-year local recurrence and lateral local recurrence rates were both 2.3% in the dose booster group, which were lower than those of the other two subgroups (local recurrence: P < 0.001; lateral local recurrence: P < 0.001). The short axis of lateral lymph nodes (>= 5 and < 5 mm) on restaging MRI was an independent risk factor for prognosis (P < 0.05). Conclusion Radiation dose boost is an effective way of increasing the response rate and decreasing recurrence rates. The restaging LLNs with short axis >= 5 mm is a predictor of poor prognosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据